Pharmaceutical industry drug prices down the general trend, how should enterprises break through? There are 3 paths

"Pharmaceutical Network Market Analysis" September 24, Sichuan Medical Insurance Bureau on the issuance of the national organization of drug centralized procurement and use of the pilot expansion of the relevant drug medical insurance payment standards (draft for comments) for public consultation.
the annex to the draft opinion clearly states that, around 25 collection of drugs, Sichuan Province will set medical insurance payment standards for 503 drugs with different pharmaceutical companies and different product regulations.
pharmaceutical industry drug prices down the general trend, how should enterprises break through? Three pathways (photo source: Pharmaceutical Network) notification indicated that the health insurance payment criteria applied to the centralized procurement and use of the pilot expansion of 25 drugs by national organizations, including selected and non-selected drugs.
patients use drugs that cost more than the payment standard, and the excess is paid for by the patient.
within the standards are shared between the patient and Medicare.
drugs that fall below the payment standard are paid at the actual price.
notice, Sichuan will implement the new payment standards from November 15, 2020.
pharmaceutical industry drug prices have become a major trend in fact, in addition to Sichuan Province, Zhejiang, Jiangxi and other provinces have previously issued a national collection of varieties of payment standards issued relevant notices.
provinces are mainly due to the intensity and time frame of implementation, but basically comply with the time limit requirements no later than 2021.
industry expects that under the normalization of collection, the impact of health insurance payment standards will be more and more extensive, especially on the higher price of the original research drugs, and the replacement effect of generic drugs will be strengthened.
you can see that the third batch of 55 selected varieties fell by an average of 53%, to a high drop of up to 95%, the price as low as 1.5 cents per piece, the price reduction is huge.
and foreign pharmaceutical companies are encountering collective Waterloo, in the three rounds of collection in the price reduction, abandonment of the phenomenon is frequent.
the future pharmaceutical industry drug prices have become a major trend.
, in this context, how should pharmaceutical companies highlight the heavy siege? The industry believes that with the establishment of payment standards, non-selecting enterprises can choose from several paths to break through.
path one is to try to get into the next round of collection.
drug companies that have not yet been selected may be hit by a new blow to their market revenues as a result of the failure of varieties to enter the market, and there may be a change in mentality.
according to the collection rules, after entering the collection, the "quantity" of the product market will be guaranteed, but the price will be reduced, quality also needs to be guaranteed.
therefore, pharmaceutical companies that choose this approach face challenges in controlling costs, capacity, and so on.
path is the transition to innovative drugs.
the normalization of centralized drug procurement, squeezing drug prices falsely high moisture has been the general trend, "do generic drugs have no way out, to do innovative drugs."
" has also become the consensus of the industry.
that innovative drugs, including biologics, some targeted drugs, and new dosage forms, could be the way forward.
, the grass-roots county market is also another new path for pharmaceutical companies to break through.
With the improvement of the level of primary care and the decline in drug prices, the ability to pay in the grass-roots market will be improved, and unsopided pharmaceutical companies can gain new growth by transitioning to the growing grass-roots market.
understood that with the gradual landing of the construction of the county medical complex, as well as the promotion of the hierarchical diagnosis and treatment system, the potential of the primary county medical market is being highlighted.
data show that China's overall drug market in the three terminal medical institutions in the overall sales scale of about 1 trillion yuan, three years of compound annual growth rate of up to 9.5%.
, the three-year compound growth of the drug market in the whole field of county hospitals was 19.6%, far higher than that of urban hospital channels.
of treatment sub-sectors, the county market in the tumor, metabolism, urology and other areas of the market growth rate is constantly improving.
, many pharmaceutical companies, including multinational pharmaceutical companies, are looking to the grass-roots market.
such as AstraZeneta and Novarma.
AstraZene cum's county market team has expanded to 4,500, with revenues in China reaching $2,659 million in the first half of 2020, up 14 per cent against the trend.
reported that this result is mainly due to the performance of the county market offset the decline in the performance of large cities.